10:32 AM EDT, 04/26/2024 (MT Newswires) -- Allogene Therapeutics ( ALLO ) said Friday it received a $15 million grant from the California Institute for Regenerative Medicine for the development of investigational advanced or metastatic renal cell carcinoma therapy ALLO-316.

The grant will fund the phase 1 study to evaluate the safety, tolerability and preliminary efficacy of ALLO-316 in patients with advanced renal cell carcinoma, the company said.

The grant will focus on completing phase 1 of the trial, expanding clinical sites for diverse patient access and supporting translational and clinical analyses to identify a recommended phase 2 regimen, Allogene said.

Price: 2.87, Change: +0.02, Percent Change: +0.53